
Anavex Life Sciences (AVXL) stock crashed on March 25 after the company unexpectedly withdrew its marketing authorization application for blarcamesine in the European Union.
The decision followed negative feedback from the European Medicines Agency (EMA), which indicated it would not issue a positive opinion for Alzheimer's treatment.